PMID- 28772041
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210109
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
VI  - 4
IP  - 3
DP  - 2017 Aug
TI  - Budget impact of intravenous iron therapy with ferric carboxymaltose in patients 
      with chronic heart failure and iron deficiency in Germany.
PG  - 274-281
LID - 10.1002/ehf2.12179 [doi]
AB  - AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with 
      intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown 
      significant improvements in exercise capacity, New York Heart Association (NYHA) 
      functional class, quality of life, and reduction of hospitalization. The aim of 
      this study was to estimate the budget impact of FCM treatment for patients with 
      HF and ID. METHODS AND RESULTS: Individual patient data from four double-blind 
      randomized controlled trials were pooled for this analysis. Expected outcomes 
      were modelled for a treatment period of 1 year, using multivariate statistical 
      methods. Associated unit costs were derived from claims data. Budget impact was 
      calculated from the perspective of the Statutory Health Insurance. Multiple 
      deterministic sensitivity analyses were performed. The annual budget impact for 
      therapy with FCM vs. no-iron therapy was euro2 735 505 and euro2 695 474 for 1000 
      patients, respectively, resulting in additional annual costs of euro40.03 for each 
      treated patient. Main costs drivers are the FCM treatment cost and cost of 
      hospitalizations due to HF worsening. FCM therapy compared with no-iron therapy 
      resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF 
      worsening (52 vs. 129 hospitalizations amounting to euro230 591 vs. euro597 078), for 
      reduced other medication (euro1 611 007 vs. euro1 679 908), fewer outpatient visits 
      (euro332 523 vs. euro378 019), and home visits (euro29 627 vs. euro40 469). Sensitivity 
      analyses showed robustness of the results. CONCLUSIONS: Therapy with FCM has a 
      minimal budget impact of euro40 031 per 1000 patients per year. This budget impact 
      translates into reduced and shorter hospitalizations and improved symptomatic 
      status of the patients.
CI  - (c) 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of the European Society of Cardiology.
FAU - Theidel, Ulrike
AU  - Theidel U
AD  - Xcenda GmbH, Hannover, 30159, Germany.
FAU - Vaatainen, Saku
AU  - Vaatainen S
AD  - ESiOR Oy, Kuopio, 70100, Finland.
FAU - Martikainen, Janne
AU  - Martikainen J
AD  - ESiOR Oy, Kuopio, 70100, Finland.
FAU - Soini, Erkki
AU  - Soini E
AD  - ESiOR Oy, Kuopio, 70100, Finland.
FAU - Hardt, Thomas
AU  - Hardt T
AD  - Vifor Pharma Deutschland GmbH, Munich, 81379, Germany.
FAU - Doehner, Wolfram
AU  - Doehner W
AD  - Center for Stroke Research and Department of Cardiology Charite 
      Universitatsmedizin Berlin, Berlin, 13353, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170703
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
PMC - PMC5542731
OTO - NOTNLM
OT  - Budget impact
OT  - Chronic heart failure
OT  - Cost
OT  - Ferinject
OT  - Ferric carboxymaltose
OT  - Iron deficiency
EDAT- 2017/08/05 06:00
MHDA- 2017/08/05 06:01
PMCR- 2017/07/03
CRDT- 2017/08/04 06:00
PHST- 2017/01/30 00:00 [received]
PHST- 2017/04/06 00:00 [revised]
PHST- 2017/04/28 00:00 [accepted]
PHST- 2017/08/04 06:00 [entrez]
PHST- 2017/08/05 06:00 [pubmed]
PHST- 2017/08/05 06:01 [medline]
PHST- 2017/07/03 00:00 [pmc-release]
AID - EHF212179 [pii]
AID - 10.1002/ehf2.12179 [doi]
PST - ppublish
SO  - ESC Heart Fail. 2017 Aug;4(3):274-281. doi: 10.1002/ehf2.12179. Epub 2017 Jul 3.